We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca Antibody Therapy for COVID-19 Fails in Late-Stage Trial
AstraZeneca Antibody Therapy for COVID-19 Fails in Late-Stage Trial
AstraZeneca’s monoclonal antibody cocktail, AZD7442, failed to prevent symptomatic COVID-19 infection in a late-stage study of individuals recently exposed to the SARS-CoV-2 virus.